Chitosan/PLGA shell nanoparticles as Tylotoin delivery platform for advanced wound healing

Wound treatment remains one of the most prevalent healthcare issues. Tylotoin is a skin repair peptide identified from salamander (Tylototriton verrucosus) and exhibits skin wound healing properties. Noticeably, the easy degradation and frequent administration limit its application in wound healing. Chitosan (CS)-PLGA-Tylotoin nanoparticles (CPT NPs) were prepared to circumvent this limitation and deliver Tylotoin for the promotion of the healing of skin wounds. Results showed that optimized CPT NPs particle size, zeta potential, encapsulation efficiency and drug loading were 297.80 +/- 5.37 nm, 20.37 +/- 0.83 mV, 81.00 % and 1.74 %, respectively. In vitro, CPT NPs exhibited good antibacterial properties and biocompatibility and persistently promoted the cell migration of HaCaT cells and HUVECs due to the long-term sustained release of Tylotoin within 14 days (64.81 %). In vivo, the scarless healing of skin wound promotion was evaluated in mouse back full-thickness wound models. We demonstrated that mouse back full-thickness wounds topically treated with CPT NPs once every two weeks exhibited better scarless healing than those treated with Tylotoin once daily. We envision that CPT NPs, as a Tylotoin delivery platform might, may be potentially utilized to in skin wounds healing in clinics in the future.

Automated summary

Wound treatment is a common healthcare issue, and Tylotoin, a peptide derived from salamander, has shown skin wound healing properties. However, its degradation and administration limitations hinder its use. In this study, Chitosan-PLGA-Tylotoin nanoparticles were developed to deliver Tylotoin for wound healing. The nanoparticles demonstrated good antibacterial properties, biocompatibility, and sustained release of Tylotoin, leading to improved wound healing in vitro and in vivo.